Clinical practice recommendations and narrative analyses emphasize the importance of maintaining ART throughout manufacturing and post-infusion, performing infectious screening and prophylaxis (HBV, CMV, Pneumocystis), managing comorbidities and drug–drug interactions (e.g., corticosteroids or tocilizumab for CRS), and selecting appropriate targets (CD19 vs. BCMA) with optimal timing for bridging therapy [36,53]. Here, CD19 is linked to congenital rubella syndrome.